Esophageal Cancer Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Statistics, Revenue, Patient Pool, Prevalence and Companies DelveInsight

(Albany, USA) DelveInsight's "Esophageal Cancer Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Esophageal Cancer, historical and forecasted epidemiology as well as the Esophageal Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Esophageal Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Esophageal Cancer treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Esophageal Cancer market.

To Know in detail about the Esophageal Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Esophageal Cancer Market Forecast - https://www.delveinsight.com/report-store/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Esophageal Cancer Market Report:
• The Esophageal Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In 2023, the 7MM reported approximately 77,000 newly diagnosed cases of esophageal cancer, with Japan recording the highest number, followed by the United States and the UK. Nearly 80% of cases in the US were among males.
• The treatment pipeline for esophageal cancer includes drugs targeting various therapeutic lines, as well as adjuvant and neoadjuvant settings. Promising candidates expected to impact the market significantly during the forecast period include zanidatamab, bemarituzumab, and others.
• The esophageal cancer market in the 7MM was valued at approximately USD 1,000 million in 2023, with the United States accounting for the largest share (40%).
• In 2023, Japan recorded the highest number of total diagnosed esophageal cancer cases (~26,000) among the seven major markets, followed by the United States.
• By age group, individuals aged 65 and older represented the largest portion of esophageal cancer cases in 2023, while the under-45 age group had the fewest cases in the United States.
• Males accounted for 80% of esophageal cancer cases in the US in 2023, with females representing 20%.
• In terms of histology-specific cases, non-squamous esophageal cancer accounted for approximately 12,500 cases, while squamous esophageal cancer was found in about 7,300 cases in the US during 2023.
• In March 2025, BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1).
• In Jan 2025, RNT Health Insights, a Chandigarh-based health-tech startup, received its second US FDA Breakthrough Device Designation for its Esophageal Cancer detection tool. The AI-assisted tool aids gastroenterologists in detecting early and advanced esophageal cancers during white-light upper GI endoscopy procedures.
• In October 2024, Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved VYLOYTM (zolbetuximab-clzb) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test.1 VYLOY is the first and only CLDN18.2-targeted therapy approved in the U.S
• In May 2024, Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-811 trial evaluating KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy met its dual primary endpoint of overall survival (OS) for the first-line treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
• In March 2024, the US FDA approved TEVIMBRA (tislelizumab) as a monotherapy for adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who had prior systemic chemotherapy that did not involve a PD-(L)1 inhibitor.
• Key Esophageal Cancer Companies: Roche, Bristol-Myers Squibb, Merck & Co, AstraZeneca, Pfizer, Sanofi, Amgen, and others
• Key Esophageal Cancer Therapies: CYRAMZA (ramucirumab), VITRAKVI (larotrectinib), Zanidatamab, Bemarituzumab, and others
• The Esophageal Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Esophageal Cancer pipeline products will significantly revolutionize the Esophageal Cancer market dynamics.

Esophageal Cancer Overview
Esophageal cancer occurs when cancerous cells form in the esophagus, the tube-like structure connecting the throat to the stomach that facilitates food transport. The disease typically starts in the inner lining of the esophagus and can spread to its other layers and to distant organs (metastasis).
Esophageal cancer Symptoms often do not manifest until the tumor becomes large enough to interfere with eating, swallowing, or digestion. The most common symptom is difficulty swallowing, often accompanied by the sensation of food being stuck in the throat, and in some cases, choking. As the tumor grows and narrows the esophagus, swallowing becomes increasingly painful and difficult.

Esophageal cancer is usually identified through symptoms or signs, followed by exams, tests, and a biopsy to confirm the diagnosis. If cancer is detected, additional tests determine its stage. While late-stage esophageal cancer has a poor prognosis, early detection allows for potentially curative treatments. Because the disease progresses gradually before noticeable symptoms appear, pre-symptomatic screening can improve outcomes. Advances in early detection, including blood tests, advanced endoscopic imaging, and artificial intelligence, offer hope for better diagnosis and treatment.

Get a Free sample for the Esophageal Cancer Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/sample-request/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Esophageal Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Esophageal Cancer Epidemiology Segmentation:
The Esophageal Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Diagnosed Prevalence of Esophageal Cancer in Adults
• Diagnosed Prevalence of Esophageal Cancer in Pediatrics
• Diagnosed Prevalence of Esophageal Cancer by Types
• Diagnosed Prevalence of Esophageal Cancer by Location
• Diagnosed Prevalence of Esophageal Cancer by Severity

Download the report to understand which factors are driving Esophageal Cancer epidemiology trends @ Esophageal Cancer Epidemiology Forecast - https://www.delveinsight.com/report-store/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Esophageal Cancer Market Dynamics
The esophageal cancer market is influenced by several drivers and barriers. Key drivers include the increasing global incidence of esophageal cancer, which raises demand for effective treatments. Advancements in medical research have led to the development of innovative therapies, such as immunotherapies and targeted treatments, enhancing patient outcomes and expanding market opportunities. Additionally, heightened awareness and improved diagnostic techniques contribute to earlier detection and intervention. However, the market faces barriers like the high cost of novel therapies, which can limit patient access and strain healthcare budgets. The complex nature of esophageal cancer, often diagnosed at advanced stages, poses challenges for effective treatment. Moreover, stringent regulatory requirements and the high failure rates in clinical trials can impede the timely introduction of new therapies, affecting market growth.

Esophageal Cancer Marketed Drugs
• CYRAMZA (ramucirumab): Eli Lilly and Company
• VITRAKVI (larotrectinib): Bayer

Esophageal Cancer Emerging Drugs
• Zanidatamab: Zymeworks/Jazz Pharmaceuticals
• Bemarituzumab: Amgen

Request for sample report @ https://www.delveinsight.com/sample-request/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Esophageal Cancer Treatment Market
Treatment for Esophageal Cancer focuses on effective diabetes management and alleviating symptoms. The first step in managing the condition is achieving glycemic control, which has been shown to reduce the risk of falls and foot ulcers. The three primary components of treatment are glycemic control, proper foot care, and pain management. Commonly prescribed medications for managing neuropathic pain include Gabapentin, Pregabalin, Tricyclic Antidepressants (TCAs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), and opioids. Alternative options include antiseizure medications like carbamazepine or lamotrigine.
Patients with Esophageal Cancer should work closely with their healthcare team to develop a personalized treatment plan. Since the effectiveness of therapy can vary from person to person, regular follow-up appointments are essential to monitor progress and adjust the treatment plan as needed. Ongoing diabetes management is also a key element of treating Esophageal Cancer.
Notable companies, including Helixmith, Vertex Pharmaceuticals, and AstraZeneca, are conducting clinical trials with their leading candidates to explore new treatments for Esophageal Cancer.

Scope of the Esophageal Cancer Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Esophageal Cancer Companies: Roche (SWX: ROG), Bristol-Myers Squibb (NYSE: BMY), Merck & Co. (NYSE: MRK), AstraZeneca (LSE: AZN), Pfizer (NYSE: PFE), Sanofi (EPA: SAN), and Amgen (NASDAQ: AMGN), and others.
• Key Esophageal Cancer Therapies: CYRAMZA (ramucirumab), VITRAKVI (larotrectinib), Zanidatamab, Bemarituzumab, and others
• Esophageal Cancer Therapeutic Assessment: Esophageal Cancer current marketed and Esophageal Cancer emerging therapies
• Esophageal Cancer Market Dynamics: Esophageal Cancer market drivers and Esophageal Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Esophageal Cancer Unmet Needs, KOL's views, Analyst's views, Esophageal Cancer Market Access and Reimbursement

To know more about Esophageal Cancer companies working in the treatment market, visit @ Esophageal Cancer Clinical Trials and Therapeutic Assessment - https://www.delveinsight.com/sample-request/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Esophageal Cancer Market Report Introduction
2. Executive Summary for Esophageal Cancer
3. SWOT analysis of Esophageal Cancer
4. Esophageal Cancer Patient Share (%) Overview at a Glance
5. Esophageal Cancer Market Overview at a Glance
6. Esophageal Cancer Disease Background and Overview
7. Esophageal Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Esophageal Cancer
9. Esophageal Cancer Current Treatment and Medical Practices
10. Esophageal Cancer Unmet Needs
11. Esophageal Cancer Emerging Therapies
12. Esophageal Cancer Market Outlook
13. Country-Wise Esophageal Cancer Market Analysis (2020-2034)
14. Esophageal Cancer Market Access and Reimbursement of Therapies
15. Esophageal Cancer Market Drivers
16. Esophageal Cancer Market Barriers
17. Esophageal Cancer Appendix
18. Esophageal Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Reports:
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Anorectal Malformation Market: https://www.delveinsight.com/report-store/anorectal-malformation-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Aspergillosis Market: https://www.delveinsight.com/report-store/aspergillosis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Bacterial Pyogenic Meningitis Market: https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market
• Becker Muscular Dystrophy Market: https://www.delveinsight.com/report-store/becker-muscular-dystrophy-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.